The passing of J. Craig Venter in April 2026 serves as a profound catalyst for a global reassessment of how humanity interacts with the fundamental building blocks of existence, moving beyond the era of genetic discovery into one of active biological fabrication. Throughout his career, Venter
The rapid advancement of biotechnology across the African continent has created an urgent demand for a new generation of policy experts capable of managing complex biological risks while fostering scientific innovation. To meet this critical need, the School of Public Health’s Pandemic Center has
Chronic obstructive pulmonary disease has long remained a primary cause of global mortality, yet the therapeutic options available to millions of suffering patients have seen little fundamental change for decades. This persistent challenge took a major turn on March 27, 2026, when AstraZeneca
The landscape of metabolic medicine is undergoing a profound transformation as a single molecule demonstrates the unprecedented ability to simultaneously regulate blood sugar, suppress appetite, and accelerate caloric expenditure. Historically, treatments for metabolic disorders focused on a
The current landscape of biological production is frequently hampered by a fundamental misalignment between the engineering of high-performing microbial strains and the logistical realities of industrial-scale purification processes. This systemic failure often manifests when a strain that performs
The landscape of gastrointestinal oncology has shifted significantly as European regulators authorize a potent new weapon for combating aggressive tumors before they have the chance to spread. The European Commission has officially approved the use of AstraZeneca’s durvalumab, commercially known as
